Yehuda Handelsman to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications Yehuda Handelsman has written about Randomized Controlled Trials as Topic.
Connection Strength
0.661
-
Lipid-lowering efficacy of obicetrapib: A comprehensive systematic review and meta-analysis. J Clin Lipidol. 2025 May-Jun; 19(3):412-421.
Score: 0.228
-
Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials. Endocr Pract. 2014 Apr; 20(4):285-92.
Score: 0.108
-
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2011 Mar-Apr; 17 Suppl 2:1-53.
Score: 0.087
-
The Avandia debate: an unhappy conclusion. J Diabetes. 2010 Dec; 2(4):221-2.
Score: 0.086
-
Colesevelam HCl improves fasting plasma glucose and lipid levels in patients with prediabetes. Postgrad Med. 2009 Nov; 121(6):62-9.
Score: 0.080
-
Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications. J Manag Care Spec Pharm. 2018 Sep; 24(9-a Suppl):S42-S52.
Score: 0.037
-
Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100?U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes. Diabetes Obes Metab. 2018 12; 20(12):2821-2829.
Score: 0.037